You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):現有眼科產品包括複方血栓通系列產品、普拉洛芬滴眼液等
格隆匯 05-11 08:00

格隆匯5月11日丨有投資者在投資者互動平台向眾生藥業(002317.SZ)提問,“請介紹下公司眼科用藥方面的佈局,以及在同業中的研發進度和產品的優勢?目前公司在中藥方面有哪些獨家品種或保密配方藥?”

眾生藥業回覆稱,公司現有眼科產品包括複方血栓通系列產品、普拉洛芬滴眼液、鹽酸氮䓬斯汀滴眼液等。其中,普拉洛芬滴眼液用於外眼及眼前節炎症的對症治療,列入多個眼科疾病診療路徑;鹽酸氮䓬斯汀滴眼液獲《過敏性結膜炎診斷和治療專家共識》推薦為急性過敏性結膜炎首選用藥、慢性過敏性結膜炎基礎用藥,公司是同通用名產品的市場領導品牌。公司佈局多個滴眼液在研產品,產品上市後將加強公司在眼科領域的競爭力。公司中藥獨家品種包括複方血栓通膠囊、腦栓通膠囊、眾生丸等。複方血栓通膠囊以其明確的血管保護作用,用於心血管疾病治療,也被多項臨牀指南及共識推薦用於視網膜靜脈阻塞等多種眼底疾病的治療,臨牀證據豐富,藥物經濟學優勢突出,連續多年在國內眼科內服中成藥領域市場佔有率排名第一位;腦栓通膠囊基於“毒損腦絡”病機學説而研發,用於治療缺血性腦卒中;眾生丸具有抗菌消炎、清熱解毒的功效,用於咽喉腫痛等咽喉疾病。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account